Compare Stocks → The Best AI Stock to Own in the World Today is Trading for Just $25 (From Banyan Hill Publishing) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ACORNASDAQ:ALNANYSEAMERICAN:ARMPNASDAQ:BVXVNASDAQ:KRBP Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACORAcorda Therapeutics$11.13$0.61▼$24.20$820K1.4119,299 shs416,900 shsALNAAllena Pharmaceuticals$0.07$0.06▼$1.17$37K1.1315.69 million shs96,558 shsARMPArmata Pharmaceuticals$2.50-1.2%$0.00$1.07▼$5.26$90.38M0.8517,229 shs4,871 shsBVXVBiondVax Pharmaceuticals$1.36$1.25▼$11.80$2.54M2.37127,289 shs23,000 shsKRBPKiromic BioPharma$2.71+2.7%$2.68$0.16▼$8.97$3.50M28,273 shs1,584 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACORAcorda Therapeutics0.00%0.00%-94.54%-96.11%-92.97%ALNAAllena Pharmaceuticals0.00%0.00%0.00%0.00%0.00%ARMPArmata Pharmaceuticals0.00%0.00%0.00%0.00%0.00%BVXVBiondVax Pharmaceuticals0.00%0.00%0.00%0.00%-28.80%KRBPKiromic BioPharma+1.54%-9.28%-12.29%+63.98%-30.89%At first glance, this chart looks like nonsense… (Ad)We can isolate the most bullish dates to buy Netflix each and every year… That’s why one former hedge fund manager calls these dates… “Hotspot Dates”But if you want the stock with “Hotspot Dates” hitting NEXT WEEK…MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACORAcorda TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AALNAAllena PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AARMPArmata Pharmaceuticals1.6554 of 5 stars3.53.00.00.00.61.70.6BVXVBiondVax PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AKRBPKiromic BioPharmaN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACORAcorda TherapeuticsN/AN/AN/AN/AALNAAllena PharmaceuticalsN/AN/AN/AN/AARMPArmata Pharmaceuticals3.00Buy$7.00180.00% UpsideBVXVBiondVax PharmaceuticalsN/AN/AN/AN/AKRBPKiromic BioPharmaN/AN/AN/AN/ACurrent Analyst RatingsLatest ALNA, ARMP, BVXV, KRBP, and ACOR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/22/2024ARMPArmata PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACORAcorda Therapeutics$117.63M0.00N/A0.02($127.17) per share0.00ALNAAllena PharmaceuticalsN/AN/AN/AN/A$0.23 per shareN/AARMPArmata Pharmaceuticals$4.53M19.95N/AN/A($0.89) per share-2.81BVXVBiondVax PharmaceuticalsN/AN/AN/AN/A($3.81) per shareN/AKRBPKiromic BioPharmaN/AN/AN/AN/A($7.25) per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACORAcorda Therapeutics-$252.85M-$203.83N/AN/AN/A-214.95%-2,206.93%-83.28%5/9/2024 (Estimated)ALNAAllena Pharmaceuticals-$48.66MN/A0.00N/AN/AN/A-287.46%-146.58%N/AARMPArmata Pharmaceuticals-$69.04M-$1.98N/AN/AN/A-1,524.51%-280.95%-52.61%5/9/2024 (Estimated)BVXVBiondVax Pharmaceuticals-$5.80M-$2.55N/AN/AN/AN/A-346.36%-29.52%N/AKRBPKiromic BioPharma-$20.95M-$15.07N/A∞N/AN/AN/A-125.75%5/13/2024 (Estimated)Latest ALNA, ARMP, BVXV, KRBP, and ACOR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/21/2024Q4 2023ARMPArmata PharmaceuticalsN/A-$0.55-$0.55-$0.55$0.68 million$1.53 million3/18/2024Q4 2023KRBPKiromic BioPharmaN/A-$4.16-$4.16-$4.16N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACORAcorda TherapeuticsN/AN/AN/AN/AN/AALNAAllena PharmaceuticalsN/AN/AN/AN/AN/AARMPArmata PharmaceuticalsN/AN/AN/AN/AN/ABVXVBiondVax PharmaceuticalsN/AN/AN/AN/AN/AKRBPKiromic BioPharmaN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACORAcorda Therapeutics3.070.330.26ALNAAllena PharmaceuticalsN/A1.581.58ARMPArmata PharmaceuticalsN/A1.161.16BVXVBiondVax PharmaceuticalsN/A4.124.12KRBPKiromic BioPharmaN/A0.220.22OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACORAcorda Therapeutics12.71%ALNAAllena Pharmaceuticals7.33%ARMPArmata Pharmaceuticals3.57%BVXVBiondVax Pharmaceuticals11.83%KRBPKiromic BioPharma10.91%Insider OwnershipCompanyInsider OwnershipACORAcorda Therapeutics2.60%ALNAAllena Pharmaceuticals3.70%ARMPArmata Pharmaceuticals85.50%BVXVBiondVax Pharmaceuticals6.03%KRBPKiromic BioPharma3.25%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableACORAcorda Therapeutics1111.24 million1.21 millionNo DataALNAAllena Pharmaceuticals35122.08 million117.57 millionNot OptionableARMPArmata Pharmaceuticals6636.15 million5.24 millionNot OptionableBVXVBiondVax Pharmaceuticals331.87 million1.76 millionNot OptionableKRBPKiromic BioPharma351.29 million1.25 millionNot OptionableALNA, ARMP, BVXV, KRBP, and ACOR HeadlinesSourceHeadlineKiromic BioPharma Reports Consistent Favorable Safety, Tolerability, and Efficacy in Deltacel-01 Clinical Trial First Three Patientsfinance.yahoo.com - April 24 at 9:15 AMKiromic BioPharma (NASDAQ:KRBP) Shares Up 1.5%americanbankingnews.com - April 24 at 2:18 AMKiromic BioPharma files to withdraw registration statementmsn.com - April 10 at 8:13 PMKiromic BioPharma Reports Favorable Safety, Tolerability, and Early Efficacy from Third Patient in Deltacel-01 Clinical Trialbusinesswire.com - April 2 at 8:18 AMEarly Efficacy Results Show Primary Lung Tumor Stabilization and Complete Disappearance of Brain Metastases in Second Patient in Kiromic BioPharma’s Deltacel-01 Clinical Trialfinance.yahoo.com - March 19 at 11:21 AMEarly Efficacy Results Show Primary Lung Tumor Stabilization and Complete Disappearance of Brain Metastases in Second Patient in Kiromic BioPharma's Deltacel-01 Clinical Trialbusinesswire.com - March 19 at 8:08 AMKiromic BioPharma Adds Virginia Oncology Associates, PC as the Second Clinical Trial Site in the Ongoing Phase 1 Deltacel-01 Trialbusinesswire.com - March 1 at 8:08 AMKiromic BioPharma to Present at the OTC Markets’ Virtual Life Science Investor Forum on March 7thfinance.yahoo.com - February 28 at 8:23 PMKiromic BioPharma to Present at the OTC Markets' Virtual Life Science Investor Forum on March 7thbusinesswire.com - February 28 at 6:30 PMResults from First Patient in Kiromic BioPharma’s Deltacel-01 Clinical Trial Indicate Tumor Reduction at Two Monthsfinance.yahoo.com - February 14 at 10:24 AMResults from First Patient in Kiromic BioPharma's Deltacel-01 Clinical Trial Indicate Tumor Reduction at Two Monthsbusinesswire.com - February 14 at 8:08 AMKiromic BioPharma Reports Favorable Early Efficacy Results from First Patient in Deltacel-01 Phase 1 Clinical Trial in Non-Small Cell Lung Cancerfinance.yahoo.com - January 29 at 9:51 AMKiromic BioPharma Reports Favorable Early Safety and Tolerability Data from First Patient Enrolled in the Phase 1 Deltacel-01 Clinical Trialfinance.yahoo.com - January 5 at 10:07 AMKiromic BioPharma Announces First Patient Dosed in Phase 1 Study Evaluating Deltacel™ for the Treatment of Non-Small Cell Lung Cancerfinance.yahoo.com - December 14 at 9:19 AMKiromic BioPharma Announces Uplisting to OTCQB Marketfinance.yahoo.com - November 16 at 5:31 PMKiromic BioPharma Announces Deltacel™ Phase 1 Clinical Trial Enters Patient Recruitment Phase at Beverly Hills Cancer Centerfinance.yahoo.com - November 9 at 10:17 AMKiromic BioPharma Inc Ordinary Sharesmorningstar.com - November 1 at 8:36 PMKiromic BioPharma and Beverly Hills Cancer Center Enter Clinical Trial Agreementfinance.yahoo.com - October 23 at 8:55 AMStaidson Beijing Biopharma (300204)uk.investing.com - September 15 at 9:22 PMKiromic BioPharma Common Stock to Begin Trading on the OTC Pink Sheets on September 14finance.yahoo.com - September 13 at 7:00 PMKiromic BioPharma Welcomes Two New Directors to its Boardfinance.yahoo.com - July 24 at 3:55 PMKiromic Biopharma Shares Down 12% After Stock Offering Prospectusmarketwatch.com - June 30 at 2:18 PMFounder of multibillion-dollar drug developer Array BioPharma leads Boulder oncology startup in $54M financing roundbizjournals.com - June 10 at 11:45 PMKRBP - Kiromic BioPharma, Inc.finance.yahoo.com - June 10 at 1:42 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAcorda TherapeuticsNASDAQ:ACORAcorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. The company's product pipeline includes Cimaglermin alfa (GGF2), a member of neuregulin growth factor family which is in Phase 1 clinical trials for recovery of neurological injury, as well as to enhance heart function in animal models of heart failure. In addition, it has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. The company was incorporated in 1995 and is headquartered in Pearl River, New York.Allena PharmaceuticalsNASDAQ:ALNAAllena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.Armata PharmaceuticalsNYSEAMERICAN:ARMPArmata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Los Angeles, California.BiondVax PharmaceuticalsNASDAQ:BVXVBiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.Kiromic BioPharmaNASDAQ:KRBPKiromic BioPharma, Inc., an artificial intelligence driven allogeneic cell therapy company, engages in developing the multi-indication allogeneic T cell therapies that exploits the natural potency of the Gamma Delta T cell (GDT) to target solid tumors. The company develops ALEXIS-ISO-1, an allogeneic GDT therapy product that targets an isoform of mesothelin; and ALEXIS-PRO-1, an allogeneic GDT therapy product that targets PD-L1. It has license agreements with CGA 369 Intellectual Holdings, Inc. and Longwood University, as well as a research and development collaboration agreement with Molipharma, S.R.L. The company also has strategic alliance agreement with Leon Office (H.K.) Ltd. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.